<SEC-DOCUMENT>0001185185-21-001785.txt : 20211202
<SEC-HEADER>0001185185-21-001785.hdr.sgml : 20211202
<ACCEPTANCE-DATETIME>20211202100143
ACCESSION NUMBER:		0001185185-21-001785
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211201
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211202
DATE AS OF CHANGE:		20211202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			India Globalization Capital, Inc.
		CENTRAL INDEX KEY:			0001326205
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-ELECTRONIC PARTS & EQUIPMENT, NEC [5065]
		IRS NUMBER:				202760393
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32830
		FILM NUMBER:		211465226

	BUSINESS ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854
		BUSINESS PHONE:		301-983-0998

	MAIL ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>indiaglob20211130_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Dec 02 14:36:22 UTC 2021 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:igc="http://www.igcinc.us/20211201" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
	<title>indiaglob20211130_8k.htm</title>
	<!-- Generated by ThunderDome Portal - 12/2/2021 2:11:47 PM -->

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div>
</div><hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/><div>
</div><hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/><div>
</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b>&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 0pt auto;"/><div>
</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">8-K</ix:nonNumeric></b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p><div>

</div><hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 0pt auto;"/><div>
</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><b>December 1, 2021</b></ix:nonNumeric></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><img alt="logo_1.jpg" src="logo_1.jpg"/></p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b><span style="text-decoration:underline">INDIA GLOBALIZATION CAPITAL, INC.</span></b></ix:nonNumeric></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in charter)</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">	<tr>	<td style="vertical-align:top;width:3.2%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b><span style="text-decoration:underline">Maryland</span></b></ix:nonNumeric></p>	</td>	<td style="vertical-align:top;width:3.3%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber"><b><span style="text-decoration:underline">001-32830</span></b></ix:nonNumeric></p>	</td>	<td style="vertical-align:top;width:3.2%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><b><span style="text-decoration:underline">20-2760393</span></b></ix:nonNumeric></p>	</td>	</tr>	<tr>	<td style="vertical-align:top;width:3.2%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation)</p>	</td>	<td style="vertical-align:top;width:3.3%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File Number)</p>	</td>	<td style="vertical-align:top;width:3.2%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p>	</td>	</tr>
</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">4336 Montgomery Ave.</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Bethesda</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span></b>&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><b><span style="text-decoration:underline">20814</span></b></ix:nonNumeric></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices)&#160;&#160;&#160;&#160;(Zip Code)</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode"><b><span style="text-decoration:underline">(301)</span></b></ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber"><b><span style="text-decoration:underline">983-0998</span></b></ix:nonNumeric></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">	<tr>	<td style="vertical-align: top; width: 3.4%; border: 1px solid black;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></p>	</td>	<td style="vertical-align: top; width: 2.6%; border: 1px solid black;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol(s)</b></p>	</td>	<td style="vertical-align: top; width: 3.8%; border: 1px solid black;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p>	</td>	</tr>	<tr>	<td style="vertical-align: top; width: 3.4%; border: 1px solid black;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle">Common Stock, $.0001 par value</ix:nonNumeric></p>	</td>	<td style="vertical-align: top; width: 2.6%; border: 1px solid black;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol">IGC</ix:nonNumeric></p>	</td>	<td style="vertical-align: top; width: 3.8%; border: 1px solid black;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></p>	</td>	</tr>
</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (&#167;240.12b-2 of this chapter)</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric>.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&#160;<b>7.01</b></p>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Regulation FD Disclosure.</b></p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On December 2, 2021, India Globalization Capital, Inc. (&#8220;IGC,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221;) issued a press to announce preliminary positive secondary end point findings from its Phase 1 clinical trial testing the safety and tolerability of IGC-AD1, IGC&#8217;s investigational new drug candidate designed to treat certain symptoms of Alzheimer&#8217;s disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information furnished under this Item 7.01, including Exhibits 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission (the &#8220;SEC&#8221;) made by IGC, regardless of any general incorporation language in such filing.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#160;<b>8.01</b></p>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Events.</b></p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On December 2, 2021, the Company issued a press release presenting preliminary positive secondary end point findings from its Phase 1 clinical trial testing the safety and tolerability of IGC-AD1, the Company&#8217;s proprietary THC-based investigational new drug candidate designed to treat symptoms of Alzheimer&#8217;s disease.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Background:</b>&#160;&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">To the best of our knowledge, this is the first human clinical trial using low doses of Tetrahydrocannabinol (&#8220;THC&#8221;), in combination with another molecule, to treat symptoms of dementia in Alzheimer&#8217;s patients. THC is a naturally occurring cannabinoid produced by the cannabis plant. It is known for being a psychoactive substance that can impact mental processes in a positive or negative way depending on dosage. THC is biphasic, meaning that low and high doses of the substance may affect mental and physiological processes in substantially different ways. For example, in some patients, low doses may relieve a symptom, whereas high doses may amplify a symptom. Ultimately, the goal of IGC&#8217;s research is to discover and analyze whether, and at what level of dosing, IGC-AD1 provides relief, as opposed to amplification of a given symptom.&#160;IGC&#8217;s trial is&#160;based on low dosing&#160;and controlled trials&#160;on patients suffering from Alzheimer&#8217;s disease.&#160;&#160;&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">A blinded, single-site, randomized, three cohort, multiple-ascending dose (MAD) clinical trial (FDA IND Number: 146069, NCT04749563) was conducted using the investigational&#160;new&#160;drug&#160;(IND)&#160;IGC-AD1. IGC received approval to proceed with the Phase 1 clinical trial from the U.S. Food and Drug Administration (FDA) on July 30, 2020. The primary&#160;objective was safety and tolerability in elderly patients suffering from Alzheimer&#8217;s disease.&#160;The secondary objective was&#160;measuring changes in neuropsychiatric symptoms (NPS)&#160;using&#160;the neuropsychiatric inventory (NPI)&#160;as well as to assess the risk of suicide using the Columbia-Suicide Severity Rating Scale (C-SSRS).&#160;&#160;The exploratory objective was&#160;to measure the&#160;pharmacokinetics (PK)&#160;and&#160;the impact of polymorphisms of&#160;the gene CYP2C9&#160;on PK.&#160;In all three cohorts, ten participants received IGC-AD1 and two received a placebo. There were at least four days of washout between the cohorts. In Cohort one, Cohort two, and Cohort&#160;three&#160;the&#160;doses were&#160;q.d. (once per day), b.i.d. (twice per day), and&#160;t.i.d. (three times per day),&#160;respectively.&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On December 1, 2021, IGC submitted&#160;the&#160;Clinical/Statistical Report (CSR)&#160;to the FDA&#160;on its Phase 1 trial entitled&#160;&#8220;A Phase I Randomized Placebo-Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 In Subjects with Dementia Due to Alzheimer&#8217;s Disease.&#8221; Data that is relevant to the&#160;Phase 1 protocol and the&#160;design of Phase 2 or Phase 3&#160;trials&#160;is presented here.&#160;The data presented here is not exhaustive.&#160;&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;At the start of the trial, the participants receiving the active drug (N=11) had an average age and weight of 81.5 years (SD 5.5) and 138.8&#160;lb&#160;(SD 24.7) respectively.&#160;The placebo participants (N=2) had an average age and weight of 75 years (SD 4.2) and 196.4&#160;lb&#160;(SD 17.0) respectively. All participants (N-13) were Puerto Rican with 69.2% being female.&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Primary Endpoint:</b>&#160;<b>Safety &amp; Tolerability</b>&#160;<b>(S&amp;T):</b>&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">S&amp;T was assessed by recording both solicited and non-solicited&#160;Adverse Events (AEs).&#160;The solicited&#160;AEs, assessed daily, were&#160;somnolence, falls, dizziness, asthenia, suicidal ideation, hypertension, psychiatric symptoms, and paradoxical nausea.&#160;All AEs were graded as mild, moderate, severe,&#160;life threatening,&#160;and serious (SAE).&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;In all three Cohorts, a) there were no SAEs, b) no life-threatening AEs, and c) no deaths.&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt;">&#9679;&#160; &#160; One AE, mild dizziness, reported in Cohort 1, was deemed to be related to IGC-AD1.&#160; All other AEs across all cohorts were deemed to be not related to IGC-AD1 or to the placebo.&#160;&#160;&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt;">&#9679;&#160; &#160; In Cohort 1, in the group that received IGC-AD1 (N=10), 50% reported hypertension, 40% reported asthenia, 30% reported somnolence and dizziness, 20% reported&#160;psychiatric symptoms&#160;and 10% reported falls. One case of dizziness was deemed by the principal investigator (PI) to be related to IGC-AD1. In the placebo group (N=2) 100% reported hypertension, and&#160;50% reported somnolence&#160;and falls.&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;In Cohort 2&#160;for&#160;the IGC-AD1 group, 60% reported psychiatric symptoms, 50% reported somnolence and asthenia, 30% reported hypertension, 20% reported nausea and dizziness, and 10% reported falls and suicidal ideation.&#160;In the placebo group 100% reported somnolence, 50% reported dizziness and hypertension.&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;In Cohort 3 for the IGC-AD1 group,&#160;70% reported somnolence, 60% reported psychiatric symptoms, 50% reported dizziness and asthenia, and 30% reported hypertension. In the placebo group 100% reported somnolence, and 50% reported&#160;hypertension and&#160;psychiatric symptoms.&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div><div>

</div><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Secondary Endpoints:</b>&#160;<b>Neuropsychiatric Inventory</b>&#160;<b>(NPI):</b>&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Neuropsychiatric Symptoms (NPS) such as delusions, hallucinations, agitation/aggression, depression, anxiety, elation/euphoria, apathy, disinhibition, irritability, aberrant motor behavior, sleep disorders, and appetite/eating disorders are prevalent in patients who have Alzheimer&#8217;s disease (Phan et al., 2019).&#160; NPS in Alzheimer&#8217;s is a significant burden on patients and caregivers, and at some point, in the progression of Alzheimer&#8217;s disease, more than 97% of patients suffer from at least one symptom.&#160;The Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) measures the severity of each symptom&#160;and&#160;establishes both individual symptom scores as well as an&#160;overall NPI score. Separately, the NPI also scores caregiver distress (NPI-D). The NPI is used by about 50% of neurologists to assess and treat Alzheimer&#8217;s patients (Fernandez et al., 2010).&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">According to the NPI Test, a reduction of 4 points or 30% in the score is considered clinically meaningful. In addition, we also used a paired 2-tailed t-test with 9 degrees of freedom to assess the statistical significance of the decrease both in the overall NPI and individual NPI domains.&#160;&#160;<br/>
&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;In Cohort 1 for those on IGC-AD1, the mean NPI decreased from a baseline 31.5 (SD 27.2) to 16.7 (SD 16.2) on day 10 (<i>p</i>&#160;=&#160;0.0044) and 14.8 (SD&#160;16.0) on day 15 (<i>p</i>&#160;=&#160;0.0095).&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 108pt;">o&#160;&#160;&#160;&#160;Individual domains that showed improvement were Agitation (<i>p</i>&#160;= .05), Dilutions (<i>p</i>&#160;= .05), Anxiety (<i>p</i>&#160;= .09), and Appetite and Eating&#160;Disorders&#160;(<i>p</i>&#160;= .01).&#160;&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;In Cohort 2 for those on IGC-AD1, the mean NPI decreased from&#160;a baseline of&#160;22.2 (SD&#160;14.8) to 10.4 (SD&#160;11.5) on day 10 (<i>p</i>&#160;=&#160;0.0026)&#160;and&#160;12.4 (SD14.7) on&#160;day 15&#160;(<i>p</i>&#160;=&#160;0.0127).&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 108pt;">o&#160;&#160;&#160;&#160;Individual domains that showed improvement were Agitation&#160;(<i>p</i>&#160;= .06), Irritability&#160;(<i>p</i>&#160;= .04), and Depression (<i>p</i>&#160;= .01).&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;In Cohort 3 for those on&#160;IGC-AD1 the mean&#160;NPI&#160;decreased from&#160;a baseline of&#160;16.0&#160;(SD14.7)&#160;to 14.6 (SD10.9) on day 10 (<i>p</i>&#160;=&#160;0.6751) and 7.9 (SD 9.0) on day 15 (<i>p</i>&#160;=&#160;0.0113).&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 108pt;">o&#160;&#160;&#160;&#160;Individual domains that showed improvement was&#160;Agitation (<i>p</i>&#160;= .06).&#160;&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;There was&#160;a&#160;non-clinically significant&#160;improvement between baseline and day 10&#160;in Cohort 3&#160;(NPI dropped less than 4 points and (<i>p</i>&#160;&gt;&gt; .05).&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 108pt;">o&#160;&#160;&#160;&#160;This&#160;may be related to the overall decrease of&#160;mean NPI between&#160;cohort baselines, Cohort 1 = 31.5, Cohort 2 = 22.2, Cohort 3 = 16.0 and that further improvement from a mean NPI = 16.0 takes longer, as measured on day 15 (mean NPI = 7.9).&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exploratory</b>&#160;<b>Endpoints,</b>&#160;<b>PK:</b>&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">PK&#160;is used to describe the absorption, distribution,&#160;biotransformation/metabolism, and excretion of a compound.&#160;It is used to correlate&#160;dosing to&#160;blood&#160;concentrations with&#160;biological&#160;effects, (Turfus&#160;S. C. et al., 2017).&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">An exploratory endpoint&#160;of the trial&#160;was PK.&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;The mean&#160;T<sub>1/2</sub>&#160;was&#160;3.30 hours (range 0.7-12.87) and 3.30 hours (range 1.05-5.7) for THC and OH-THC respectively.&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;The mean T<sub>max</sub>&#160;was 2.15 hours (range 1.0-3.5) for&#160;&#916;<sup style="vertical-align:top;line-height:120%;font-size:pt">9</sup>-THC (THC), and 1.9 hours (range 1.0-4.0) for the active metabolite -11-OH-&#916;<sup style="vertical-align:top;line-height:120%;font-size:pt">9</sup>-THC (OH-THC).&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;The mean AUC<sub>last</sub>&#160;was 5.58 h*ng/ml&#160;(range&#160;1.31-11.35)&#160;for THC and 17.03 h*ng/ml&#160;(range 5.16-65.9)&#160;for OH-THC&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exploratory Endpoints,</b>&#160;<b>PK and Genotyping</b>&#160;<b>(continued):</b>&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The CYP2C9 gene encodes cytochrome P450 2C9 enzyme that is the main enzyme that is known to metabolize and eliminate S-warfarin, tolbutamide, phenytoin, losartan, diclofenac, and celecoxib. It is a member of the cytochrome P450 superfamily and is highly polymorphic.&#160; Phenotypes are stratified into groups including poor (PM), intermediate (IM), normal (NM), and ultra-rapid (UM) metabolizing phenotypes (Gaedigk, et al., 2008;&#8239;Caudle and&#160;Dunnenberger., 2017).&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div><div>

</div><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The two most common allelic variants, CYP2C9*2 and CYP2C9*3 have been shown to cause reductions in enzyme activity of 30% and 80% respectively (Crespi&#160;CL et al., 1997,&#160;Takanashi&#160;K et al., 2000).&#160; The carriers of CYP2C9*1 of the homozygous *1/*1 genotype are designated extensive or NM. Those carrying one of the heterozygous *1/*2 or *1/*3 alleles are designated IM. Those carrying the *2/*2, *2/*3, or *3/*3 alleles are designated as PM. In general, the metabolic ratio of unchanged drug to metabolite is higher in PM.&#160;&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;Sixty-two percent of the study population (N=13) had a&#160;polymorphism&#160;of&#160;CYP2C9 characterized as Intermediate Metabolizer (IM) with the remaining were Normal Metabolizer (NM).&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;For THC, the&#160;T<sub>1/2</sub>&#160;was&#160;1.73&#160;hours&#160;for the NM group and 5.09&#160;hours&#160;for the IM group.&#160;For OH-THC the&#160;T<sub>1/2</sub>&#160;was 2.98 and 3.51 hours for the NM and IM groups, respectively.&#160;&#160;&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;THC&#160;T<sub>max</sub>&#160;was&#160;2.38&#160;and 2.00&#160;hours&#160;for NM and IM, respectively.&#160;&#160;OH-THC&#160;T<sub>max</sub>&#160;1.75 and 2.00 hours for NM and IM, respectively.&#160;&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;THC AUC<sub>last</sub>&#160;was&#160;6.72&#160;h*ng/ml and&#160;4.82&#160;h*ng/ml for NM and IM, respectively.&#160;OH-&#160;THC AUC<sub>last</sub>&#160;was&#160;12.30&#160;h*ng/ml and&#160;20.18&#160;h*ng/ml for NM and IM, respectively.&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 72pt;">&#9679;&#160;&#160;&#160;&#160;AUC metabolite / Drug ratio was&#160;1.8 and 4.2 for NM and IM, respectively.&#160;&#160;&#160;&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">IGC-AD1 is investigational and has not been approved as a new drug by any regulatory body in any country. Although the Phase 1 trial above has been completed, and certain data has been collected, the investigational new drug&#8217;s safety and efficacy have not yet been established. As Phase 2 trials require FDA approval, it cannot yet be estimated if and when the FDA may approve a Phase 2 trial to commence.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Any forward-looking statements contained herein are based largely on IGC&#8217;s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC&#8217;s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company&#8217;s failure or inability to commercialize one or more of the Company&#8217;s products or technologies, including the investigational new drug or formulation described in this release, or failure to obtain FDA approval for the investigational new drug or additional clinical trials; testing results from human clinical trials that may not be favorable or as anticipated or consistent with the results obtained from Phase 1 trials; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA&#8217;s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC&#8217;s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Reports on Form 10-K filed with the SEC on June 14, 2021, and Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2021, and October 29, 2021, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.&#160;All forward-looking statements contained in this filing and press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01</b></p>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Statements and Exhibits.</b></p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i>Exhibits.</i></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration:underline">Exhibit No.</span></b></p>
			</td>
			<td style="vertical-align:middle;width:30.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration:underline">Description</span></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align:middle;width:30.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_312236.htm" style="-sec-extract:exhibit;">Press release issued by India Globalization Capital, Inc. on December 2, 2021.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.4%;">104</td>
			<td style="vertical-align:middle;width:30.9%;">Cover Page Interactive Data File (formatted as Inline XBRL)</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:4.9%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>INDIA GLOBALIZATION CAPITAL, INC.</b></p>
			</td>
			<td style="vertical-align:top;width:1.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:1.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.4%;">&#160;</td>
			<td style="vertical-align:top;width:1.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated:&#160;&#160;December 2, 2021</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:3.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/&#160;Claudia Grimaldi</p>
			</td>
			<td style="vertical-align:top;width:1.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.3%;">&#160;</td>
			<td style="vertical-align:bottom;width:3.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:&#160;Claudia Grimaldi</p>
			</td>
			<td style="vertical-align:top;width:1.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:&#160;Vice President and PFO</p>
			</td>
			<td style="vertical-align:top;width:1.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.4%;">&#160;</td>
			<td style="vertical-align:top;width:1.2%;">&#160;</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001326205</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="igc-20211201.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context id="c0">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+OXrY/npUeQWhkTxVlMhSGiCsycCjKJ+JQdb/ktnN2qTsOUq3n6YaHc2z11YQ4jWHDu242D2/5DbBuyq5SdVLkOrG1I0/GV1/423A2n02pY/dKz95yiYV4CgIhXk2PuZa] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_312236.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_312236.htm</title>
	<!-- Generated by ThunderDome Portal - 12/2/2021 2:12:15 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 99.1</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt;"><img alt="logo_1.jpg" src="logo_1.jpg"></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Phase 1 Clinical Trial Data Indicate IGC</b>&#8217;<b>s THC-based Investigational New Drug May </b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Reduce Symptoms of Dementia in Alzheimer</b>&#8217;<b>s Patients </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">POTOMAC, MD, December 2, 2021, (NYSE American: IGC), India Globalization Capital, Inc. (IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The investigational new drug, IGC-AD1, is IGC&#8217;s proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimer&#8217;s disease. The results of the clinical trial have been submitted in the Clinical/Statistical Report (&#8220;CSR&#8221;) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Alzheimer&#8217;s disease impacts about 50 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering. Currently, there is no FDA-approved medication to alleviate symptoms of dementia, such as agitation, due to Alzheimer&#8217;s disease.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To the best of our knowledge, this is the first human clinical trial combining low doses of THC with another molecule to treat symptoms of dementia in Alzheimer&#8217;s patients. THC is a naturally occurring cannabinoid produced by the cannabis plant. It is known for being a psychoactive substance that can impact mental processes in a positive or negative way depending on dosage. THC is biphasic, meaning that low and high doses of the substance may affect mental and physiological processes in substantially different ways. Our trial is based on low or microdosing, which is hypothesized to potentially have a promising effect on Alzheimer&#8217;s patients.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As previously disclosed the recently closed trial was approved to proceed by the U.S. Food and Drug Administration (FDA) on July 30, 2020. The trial included three cohorts, with 12 patients in each cohort. Patients in Cohort-1, Cohort-2 and Cohort-3 received the medication once, twice, and thrice per day, respectively, for 14 days. To evaluate one of the secondary end points for the study, neuropsychiatric symptoms of patients, across all cohorts, were assessed on day zero of each cohort to establish a baseline, as well as on day 10, and day 15 of each cohort.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Based solely on the data collected over the course of the Phase 1 trial, we saw evidence of clinical improvements in anxiety, depression, and agitation. On the anxiety and depression scales, we documented a decrease of approximately 50% to 60% in patients who received the drug. For agitation, we documented a decrease of approximately 35% to 60% in patients who received the drug. The degree of the decrease varied by cohort. Based on the preliminary data obtained to date, IGC estimates that the most effective dosage of the drug may be once or twice per day, depending on the symptom. As previously disclosed, we have received an initial patent, and filed additional patents to protect our intellectual property.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As this was a Phase 1 trial, data collected related to neuropathic symptoms are preliminary in nature and are not a guarantee of future positive results. Nevertheless, IGC is encouraged by these initial promising and exciting results, as the potential to improve the quality of life of Alzheimer&#8217;s patients and their caregivers could be significant if similar results are repeated in future trials with larger patient pools. We are in the process of using the results from this Phase 1 study to design and subsequently pursue, based on FDA approval, a placebo-controlled, multi-site trial with a significantly expanded patient population to further test the efficacy of IGC-AD1 on agitation, anxiety, and depression in Alzheimer&#8217;s patients. The details of a clinical trial process in general are documented in IGC&#8217;s annual report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">IGC-AD1 is an investigational new drug that has not been approved as a medication by any regulatory body in any country. Although the Phase 1 trial has been completed, and certain data has been collected, IGC-AD1&#8217;s safety and efficacy need to be further established through trials on larger and more diverse groups of Alzheimer&#8217;s patients.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About IGC: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">India Globalization Capital, Inc. (IGC) engages in the development of cannabinoid-based therapies for healthcare applications. The company currently operates two lines of business: life sciences and infrastructure. The life sciences business recently completed the first safety and tolerability clinical trial to treat symptoms of Alzheimer&#8217;s patients using a THC-based investigational new drug. In addition, we produce and sell over-the-counter hemp-based women&#8217;s health products, including for post menstrual symptoms (PMS) and dysmenorrhea. The second line of business is an infrastructure business based in India. IGC headquartered in Potomac, MD.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">www.igcinc.us, www.igcpharma.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Forward-Looking Statements: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on IGC&#8217;s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC&#8217;s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company&#8217;s failure or inability to commercialize one or more of the Company&#8217;s products or technologies, including the investigational new drug or formulation described in this release, or failure to obtain FDA approval for the investigational new drug or additional clinical trials; testing results from human clinical trials that may not be favorable or as anticipated or consistent with the results obtained from Phase 1 trials; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA&#8217;s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC&#8217;s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Reports on Form 10-K filed with the SEC on June 14, 2021, and Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2021, and October 29, 2021 as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Claudia Grimaldi</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">info@igcinc.us</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Phone: 301-983-0998</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>igc-20211201.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Dec 02 14:36:22 UTC 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" targetNamespace="http://www.igcinc.us/20211201" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:igc="http://www.igcinc.us/20211201" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20211201_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20211201_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20211201_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+OXrY/npUeQWhkTxVlMhSGiCsycCjKJ+JQdb/ktnN2qTsOUq3n6YaHc2z11YQ4jWHDu242D2/5DbBuyq5SdVLkOrG1I0/GV1/xR9vmfZ9PCFt3J24FtUjaIboczOc++F9] CSR-->
      <link:roleType roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>igc-20211201_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Dec 02 14:36:22 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="igc-20211201.xsd#DocumentAndEntityInformation" roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.igcinc.us/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+OXrY/npUeQWhkTxVlMhSGiCsycCjKJ+JQdb/ktnN2qTsOUq3n6YaHc2z11YQ4jWHDu242D2/5DbBuyq5SdVLkOrG1I0/GV1/YpIumu8e76846faJuGL39iWN+iZTrZhl] CSR-->
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="22" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>igc-20211201_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Dec 02 14:36:22 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+OXrY/npUeQWhkTxVlMhSGiCsycCjKJ+JQdb/ktnN2qTsOUq3n6YaHc2z11YQ4jWHDu242D2/5DbBuyq5SdVLkOrG1I0/GV1/v1wLFicTAVy1v3YnsW61wOXI1KOgbBql] CSR-->
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl0" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl0" xml:lang="en-US">Written Communications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl0" xml:lang="en-US">Soliciting Material</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl0" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>igc-20211201_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Dec 02 14:36:22 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="igc-20211201.xsd#DocumentAndEntityInformation" roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.igcinc.us/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="igc-20211201.xsd#igc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+OXrY/npUeQWhkTxVlMhSGiCsycCjKJ+JQdb/ktnN2qTsOUq3n6YaHc2z11YQ4jWHDu242D2/5DbBuyq5SdVLkOrG1I0/GV1/v1wLFicTAVx9+aOIhVKXAI3lbIRIQLAD] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo_1.jpg
<TEXT>
begin 644 logo_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %=H:71N97D@
M0G)A=6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S$X  "2
MD@ "     S$X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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MY3<YMMW9ZI1117G %%%% '#?&'1K[7_AI?:=I-N]S=S2PB.-.I/F#]/>N;\
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>indiaglob20211130_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="igc-20211201.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <dei:DocumentType contextRef="c0">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c0">2021-12-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c0">INDIA GLOBALIZATION CAPITAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">MD</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c0">001-32830</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c0">20-2760393</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">4336 Montgomery Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Bethesda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">20814</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(301)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">983-0998</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c0">Common Stock, $.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">IGC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0">0001326205</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140130078722184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INDIA GLOBALIZATION CAPITAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IGC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2760393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4336 Montgomery Ave.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bethesda<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">983-0998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ -5""4Y>*NQS
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MK84: ]@W.9 $E^2J=51=Z7FFUS>36TGHX-R#8._AE8P=S8\?=_<#4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( #50@E,'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ -5""
M4^'W*P?N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ -5""4YE<G",0!@  G"<  !,              ( !
MS $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  U4()3D<%FLD8$
M  !?$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ -5""4Y^@&_"Q @  X@P   T              ( !
MB0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  U4()3EXJ[',     3 @
M"P              @ %E#P  7W)E;',O+G)E;'-02P$"% ,4    "  U4()3
M.JJBYT !   \ @  #P              @ %.$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ -5""4R0>FZ*M    ^ $  !H              ( !NQ$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ -5""4V60
M>9(9 0  SP,  !,              ( !H!(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  ZA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="indiaglob20211130_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.igcinc.us/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="indiaglob20211130_8k.htm">indiaglob20211130_8k.htm</File>
    <File>ex_312236.htm</File>
    <File>igc-20211201.xsd</File>
    <File>igc-20211201_def.xml</File>
    <File>igc-20211201_lab.xml</File>
    <File>igc-20211201_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo_1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "indiaglob20211130_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "igc-20211201_def.xml"
     ]
    },
    "inline": {
     "local": [
      "indiaglob20211130_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "igc-20211201_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "igc-20211201_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "igc-20211201.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "igc",
   "nsuri": "http://www.igcinc.us/20211201",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "indiaglob20211130_8k.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.igcinc.us/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "indiaglob20211130_8k.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "igc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.igcinc.us/20211201",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001185185-21-001785-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001185185-21-001785-xbrl.zip
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MGZH%17O4:KLRV3' 2Q/E+QOXIW'=4H_M9694' 5LH@**"S+R>Y;,A0S&,6_
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M>[[;'^[M/;_=</AQ>GG57Y?H=[80_M;60%,9XQ?J+L$A^,OE_P)02P,$%
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M+/P Y>;#O(VOJZVKV%+Z OW0?JB]TV),L2L13G33OV#^/TQ2.:LQ/7;,D;(
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MV% FM"+F0""1%=>8,L-^A).4-HR1L >T+D?+$KJP_=A@GWPD'KDJ 49BZ=>
M/G^QM#[O4-OMIP.[ZBK>-]O78XS2V&1N@!U$,&]*$,H<>QBPL]3W!#(&$"]U
M'1<%NZADKZ^B$0]"]"UBA,JG6_]WL U-K@(:7?(E@T CV?N("+A#6#RC5 CU
MCBGG=Q7[F@#A*N!+LG=4+]X=D_9PF#"WQ, >1,#'R1*Z$%O5)C6B2:D+R ?9
ML0G^^9?6]_4)W]MMKVUWSD3 ='GF6VCZH M9PL\"-L .XD'8E""4.;: W5OJ
MT[DY-M ()'[C'PEX $<'T4*$HL?4K?Z70>KZIT&!&2?+SQ"% /\!4$L#!!0
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MXVZJ;%)U0RWHVU-FYT+=%&6?$@=>P[X2,"]S?P0/<@RY(T<2"MJ&%/8/<F@
M5"F@;N0#A#]K!'@NQ+R"[>^8(^Z;6%H7\,XI$K9];<Y-0$ @#+8]ILEOM;4
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MEZDW?E!^TS"^^26D?NC(5 FX!&N!C="B8$(6RB#LT/2(U=W(3J>RO*6Z)V;
M^XR/$O4ZID?A^^+*_%O![O4+=F/*YZ87Z3[+7SS4+UD.5)->5N[_:U;N_GA)
M-8T]&GW;V5GEY*W_>>R>E-#JKOL"^V_<_(!-IJ[C>$)U3B_#_,1\<@Q8\"MQ
M*@<+*)$^."1%@=D@6]GZLLL 5AB?.7FB *C.S-!;&S.U+EG?E"[XR-2D:-B\
M-<07D&SP,G VB?"-?V+VGX9I68T]?9),<W[#-V)JL#(8+C@4DL0POW/A-3;T
MY@!\-\A[WR\4/'P- = K_\BK:1K-#T5UAVIA7V/)/8J*J$PM*AYYYF*=66E;
M)EGDA'+=7S^_.=_91"7UR1((OKT [VNP/=[_:NE^[\5E>_#JYK2?"=VO8N*5
MP:Y++[>4>R"T32IMTG5?^;3DI9T.5@&G) 4G<SW)[99%N=3;1U217:PWX8VR
MDEZD_50#]']3S)^B[L!:P:H6[X3SS2?[8"L.?1W9<U-*_6R&)9T!T@-MC6=;
MUM9[>Z%W77]JQ^ZRVVNS%^=7S]OGO=_;@][5)>NTKWN#]CGHULO.4G]I+1R8
MNO40!^LKX$^$S"6];,!$WO>DH3<^\$EENFS M#\=&7=Q$_"P[)DN&H,?1, *
MZ9\.[N?SP\< DQ)0&P9)$DP/Y6ON\87WF5'ROC7_=(#7X[K*_/%X2K8YEC7V
M''=3!<7'YB^Y)I\+W9=\*@[_W@C_C,0]P/<0*'3_BF^20+>40B>TD7A]=O6W
M1?K'U2(;Y\J>M_L#K? =EV:W?]2L]8K+5P9(8<!QX]#C<^FN@KGFS@XG@H-2
M.&'L._KE.D"8V2]H=9E.120#I^B$W> >C TFL@\B!/H3[F$;7R"+/LB9Q\=;
M)R/NQ>*X7GD:^GM"AZ?XYHYYAXZX>CWP,&8OQ7SK!#24V;#V+&/W0>_?T94<
M=CE6'M.,3XX]U[\]C.V)F'(8D,WHM]Q0<L>VAAK=M Q3G\7.EKJ+:<_/MF(7
M<V0 4_5J%R<T8FD(QHIQXR"-,'PUFWH^+E^2A(?U^OW]O3X;1IX>1..Z91B-
MNNO+0!=TCS?<0X43YCJ$DZS3_](T]K^_7?RZ^W__^]H.T]D;?[?EO-N_&[^9
M^Z^ZZ?V+_:BU_])Z^VHPC[W]._N=X?V<M-*[F_CGP>L+<2'NS^<_M7YZ^7:O
MMQ<.[^SN[.UY^_QJNIN,>O%E_X_[;K,=O/N]?M9J-M\<[(^N1CUCWOREXS?N
MY\;=;V^X_>O+_E74LV;_OGH=O:G[X2OQRV^3V\'L5^]BTG_A=N*YW7G[\N=_
M__R+,ZS?)OZE]<<@OGKU1\/?>\-_LJUWIOGFE^;;WW[JIE;3ZEKUW>[P>3K_
M8[?O_'I^>Q6],'M&_<6O9KUI-=J6;UCAF[KS\EUK=^Z^^;79&?<FKV^MZ_1W
M_G^LT[_1-"10QA36Z$TO<WDIOYB'IB-&BR8JZQ +6Q\'=_5.[V65L!8?IB7
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M.,C"<I"5BXWN,5AY.0^S<_'Q"O#S\?(=$Q21/BXH+"5\C$]<45Q*1E;^I+R
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MLG+H4 GI^1'?S;4BV1XSJPQ'!>.J0?J;YY>FG]\&?]TX=P?^!5!+ 0(4 Q0
M   ( #50@E/O[ZZ,W@T  , L   -              "  0    !E>%\S,3(R
M,S8N:'1M4$L! A0#%     @ -5""4U,3/V! !   X P  !
M ( !"0X  &EG8RTR,#(Q,3(P,2YX<V102P$"% ,4    "  U4()3CSO4WNT%
M   %*@  %               @ %W$@  :6=C+3(P,C$Q,C Q7V1E9BYX;6Q0
M2P$"% ,4    "  U4()3M^TM)F8(  !450  %               @ &6&
M:6=C+3(P,C$Q,C Q7VQA8BYX;6Q02P$"% ,4    "  U4()3A!- HJ,%  !4
M*P  %               @ $N(0  :6=C+3(P,C$Q,C Q7W!R92YX;6Q02P$"
M% ,4    "  U4()3*?QQJ?XD  #JM@  &               @ $#)P  :6YD
M:6%G;&]B,C R,3$Q,S!?.&LN:'1M4$L! A0#%     @ -5""4[ DP;1I$
MQRH   H              ( !-TP  &QO9V]?,2YJ<&=02P4&      < !P"]
) 0  R%P

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
